PIRS Pieris Pharmaceuticals
- 11.2200
- -0.1100-0.97%
- 11.2200
- 0.00000.00%
Pieris Pharmaceuticals News
Looking Into Pieris Pharmaceuticals's Recent Short Interest
Pieris Pharmaceuticals's (NYSE:PIRS) short percent of float has risen 1664.29% since its last report. The company recently reported that it has 24 thousand shares sold short, which is 2.47% of all reg
Express News | Pieris Pharmaceuticals Received Nasdaq Notice Stating For Last 10 Consecutive Business Says, Closing Bid Price Was At $1 Or Greater
Express News | Pieris Pharmaceuticals Inc: Regained Compliance With Nasdaq Listing Rule 5550(a)
Express News | Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Express News | Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Little Excitement Around Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues As Shares Take 27% Pounding
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) shareholders won't be pleased to see that the share price has had a very rough month, dropping 27% and undoing the prior period's positive performance. Fo
Pieris Pharmaceuticals To Carry Out 1-for-80 Reverse Stock Split On April 23rd, 2024
April 20th - $Pieris Pharmaceuticals(PIRS.US)$ is about to implement a 1-for-80 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from April 23rd, 2024.$Pieris Pha
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
BOSTON, MA / ACCESSWIRE / April 19, 2024 / Pieris Pharmaceuticals, Inc. today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value
Express News | Pieris Pharmaceuticals Inc: Common Stock Trading on a Reverse Split-Adjusted Basis Will Begin at Market Open on Tuesday, April 23, 2024.
Express News | Pieris Pharmaceuticals- Announces 1-for-80 Reverse Stock Split
Pieris Pharmaceuticals Announces Repositioning Plan To Optimize Potential Milestones And Royalties Including Discontinuation Of R&D Efforts And Workforce Reduction
Pieris Pharmaceuticals Announces Repositioning Plan To Optimize Potential Milestones And Royalties Including Discontinuation Of R&D Efforts And Workforce Reduction
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersEtao International Co (NASDAQ:ETAO) shares increased by 180.5% to $0.4 during Wednesday's pre-market session. The company's market cap stands at $40.4 million. Jaguar Health (NASDAQ:JAGX) stock
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersGeron (NASDAQ:GERN) stock increased by 90.8% to $3.34 during Thursday's after-market session. The market value of their outstanding shares is at $1.8 billion. Madrigal Pharmaceuticals (NASDAQ:M
Prime Medicine Names Foghorn Therapeutics' CFO to Be Its New Finance Chief
Prime Medicine (PRME) said Friday it has selected a new chief financial officer, with Allan Reine slated to join the biotechnology genetic therapies company on Jan. 17. Reine joins the company from hi
Investors Don't See Light At End Of Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Tunnel And Push Stock Down 27%
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersYS Biopharma Co (NASDAQ:YS) shares moved upwards by 72.0% to $1.34 during Friday's pre-market session. The company's market cap stands at $124.6 million. Longeveron Inc. - Subscription Right (N
Is Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive Analysis
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know
Pieris Pharmaceuticals Says Patient Dosing in Cancer Drug Trial Triggers Milestone Payment From Boston Pharmaceuticals
Pieris Pharmaceuticals (PIRS) said Thursday the dosing of the first patient in a phase 1/2 trial of cancer drug candidate BOS-342 triggered a milestone payment from Boston Pharmaceuticals. The study w
Analysis
Price Target
No Data
